🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT06699043
Active, not recruiting Not applicable

Study of Two Different Putty Bone Grafts in Treatment of Intrabony Defects with the Aid of Intramarrow Penetration Technique

NCT06699043 · tracked via the Priya Life Science Egypt tracker
Sponsor
Afaf Mansour Dao Abdelslam
Phase
Not applicable
Started
2024-06-01
Last updated
2024-11-21

Condition(s) studied

Intrabony Defects in Chronic Periodontitis

Investigational drug(s) / intervention(s)

nanocrystalline hydroxyapatite in putty formDemineralized Bone Matrix allograft putty

nanocrystalline hydroxyapatite in putty form: decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. * Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa * The intrabony defects in Group I will be received nanocrystalline hydroxyapatite in putty form as grafting material (NanoBone® SBX Putty).

Demineralized Bone Matrix allograft putty: decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. • Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa • The intrabony defects in Group II will be received Demineralized Bone Matrix allograft putty as grafting material, in both groups will be use membrane to cover of the graft materials and finally will be sutured the flap.

Study summary

to evaluate and compare efficacy of two different putty forms for both Demineralized Bone Matrix allograft (DBM) and nanocrystalline hydroxyapatite (NCHA) in treatment of intrabony defects with the aid of intramarrow penetration,

A total of twenty patients will be diagnosed with stage III grade B periodontitis according to the Caton classification. They will be selected from the clinic of Department of Periodontology and Oral Medicine, Faculty of Dentistry, Mansoura University

Patients will be classified into two groups:

* Group I: in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of nanocrystalline hydroxyapatite in putty form as grafting material.
* Group II: in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of Demineralized Bone Matrix allograft putty as grafting material.

Clinical assessment:

including the following parameters:

1. Plaque Index (PI).
2. Gingival Index (GI).
3. Clinical Attachment Level (CAL)
4. Probing Depth (PD) Radiological parameters

* The height of the defect: Distance from the CEJ to the alveolar crest (AC)
* Depth of the defect: Distance from CEJ to the base of the defect
* Width of the defect: Highest point of the AC to the root adjacent to the defect
* Defect angle: Two lines that represent the root surface of the involved tooth and the bone defect surface

Eligibility

Sex
ALL
Min age
25 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Both genders with 25-55 years of age. * Patients with intrabony defects in the Stage III Grade B periodontitis. * Individuals with probing depth ≥ 5mm. * Individuals with clinical attachment loss ≥ 5mm. * Presence of at least one or more intrabony defect ≥ 3 mm on the radiographs. * patients who had not periodontal therapy in the previous 6 months. Exclusion Criteria: * Patient with stage I, II and IV periodontitis. * Pregnant or lactating mothers. * Patients having any systemic disease. * allergies to Local anesthesia and chlorhexidine, antibiotics, and analgesics will be excluded.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry , Mansoura University Al Mansurah Dakahlia Governorate

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06699043 on ClinicalTrials.gov ↗ ← All trials in Egypt